Evolus to Participate in Two Upcoming Investor Conferences

April 29, 2019

IRVINE, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, announced today that members of management will be participating in two upcoming investor conferences.

Event:	SunTrust 5th Annual Life Sciences Summit
Format:	1x1 Meetings
Date:	Tuesday, May 7, 2019
Location:	Lotte New York Palace, NY

Event:	Bank of America Merrill Lynch Healthcare Conference 2019
Format:	Presentation and 1x1 Meetings
Date:	Tuesday, May 14, 2019
Time:	3:40pm PT
Location:	Encore Hotel, Las Vegas, NV

An audio webcast of Evolus's presentation at the Bank of America Merrill Lynch Healthcare Conference will be available on the investor relations section of Evolus's website at investors.evolus.com. A replay of the webcast will be available for 90 days after the date of the presentation.

About Evolus, Inc.

Evolus is a performance beauty company with a customer-centric approach focused on delivering breakthrough products. In 2019, the U.S. Food and Drug Administration approved Jeuveau™ (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure™ technology. Jeuveau™ is powered by Evolus' unique technology platform and is designed to transform the aesthetic market by eliminating the friction points existing for customers today. Visit us at: www.evolus.com.

Jeuveau™ is a trademark of Evolus, Inc.

Hi-Pure™ is a trademark of Daewoong Pharmaceutical Co, Ltd.

Evolus, Inc. Contacts:

Investors Contacts:
Ashwin Agarwal, Evolus, Inc.
Vice President, Finance, Investor Relations & Treasury
Tel: +1-949-284-4559
Email: IR@Evolus.com

Brian Johnston, The Ruth Group
Tel: +1-646-536-7028
Email: IR@Evolus.com

Media Contacts:
Crystal Muilenburg, Evolus, Inc.
Vice President, Corporate Communications & Public Relations
Tel: +1-949-284-4506
Email: media@evolus.com

Source: Evolus